Parenteral Iron Therapy in Pregnancy

Dawson, D W; Goldthorp, W. O.; Spencer, Donald B.

doi:10.1111/j.1471-0528.1965.tb01378.x

Cited by 20 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…j j | tg '^M' eol §^* §^s^' s S'l! S The adequacy of the haematological response in iron deficiency anaemia to total-dose irondextran infusion has been previously reported by a number of authors (Gartlan, 1964;Varde, 1964;Basu, 1965;Bonnar, 1965;Clay et al, 1965;Goldthorp, Spencer & Dawson, 1965;Lane & Scott, 1965;Manson, 1965), but these studies related to patients seen in obstetric and gynaecological practice. The results in the present series indicate that a similar satisfactory response can be obtained in patients within a wide age range and suffering from a variety of clinical conditions.…”

Section: Discussionmentioning

confidence: 88%

The treatment of iron-deficiency anaemia by iron-dextran infusion, with special reference to the effect on blood-grouping, coagulation, sedimentation and haemolysis

Groden

Whitelaw

Will

1968

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

The treatment of iron-deficiency anaemia by iron-dextran infusion, with special reference to the effect on blood-grouping, coagulation, sedimentation and haemolysis

Groden

Whitelaw

Will

1968

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…It has been described by several authors (Basu, 1963;Bonnar, 1965;Marchasin and Wallerstein, 1964;Dawson, Goldthorp, and Spencer, 1965) and is generally called 'total dose infusion' (TDI).…”

mentioning

confidence: 99%

Intravenous iron-dextran: studies on unsaturated iron-binding capacity

Cox¹,

Moss²,

Bremner³

et al. 1968

J Clin Pathol

View full text Add to dashboard Cite

From Fisons Pharmaceuticals Limited, Holmes Chapel, Cheshire SYNOPSIS A method is described for measuring the plasma unsaturated iron-binding capacity in the presence of very high concentrations of iron as iron-dextran. The procedure utilizes 59Fe to label the apotransferrin with subsequent separation of ionic iron from transferrin-bound iron on an ion exchange or Sephadex G.25 column.The unsaturated iron-binding capacity has been measured in rabbits and dogs after intravenous injection of iron-dextran and in human subjects after total dose infusion of iron-dextran. No evidence of saturation of the unsaturated iron-binding capacity was found even when the plasma iron values were greater than 40,000 .tg Fe/100 ml.The treatment of iron-deficiency anaemia by a single intravenous infusion or injection of the total iron requirements in the form of iron-dextran is now an established technique. It has been described by several authors (Basu, 1963; Bonnar, 1965;Marchasin and Wallerstein, 1964;Dawson, Goldthorp, and Spencer, 1965) and is generally called 'total dose infusion' (TDI).It is essential that when any iron preparation is introduced into the bloodstream in such quantities (2-3 g as Fe) no large amounts of ionic iron should be precipitated or released. There is no precipitation of iron from iron-dextran (Imferon2) over a wide pH range in plasma and none of the proteins at iron concentrations of up to 5% (Golberg, 1958). The slow clearance over several days of iron-dextran from the bloodstream after TDI gives an indication of its stability in blood (Marchasin and Wallerstein, 1964).It has been shown in studies in vitro (Fielding and Smith, 1963) that at high concentrations of iron-dextran haemolysis of red blood cells can take place. They attributed this to the presence of ionic iron and calculated that around 0-3 % of the total iron was in this uncomplexed state. Using polarographic and electrophoretic techniques it has been demonstrated that atpH 5 *6, 1 to 2 %of the total iron in iron-dextran is present in the ferrous state,

show abstract

“…Similar reactions have never been reported in man, although Jectofer has been available for clinical use since 1961 (Akemi 1970, Daily 1965, Dawson et al 1965, Even & van Kessel 1964, Galloway & Gatenby 1964, McCurdy 1964. Neither parent nor litter parameters were adversely affected by treatment with doses of 1, 4 or 16 mg Fe3+/kg on days 12-15 of pregnancy, while at the 50 mg Fe3+/kg doses focal necrosis of the liver was observed in almost 100 % of the pregnant rats.…”

Section: Discussionmentioning

confidence: 72%

Teratological, Peri‐ and Postnatal Studies on Ferastral®, an Iron‐poly (sorbitol‐gluconic acid) complex

Flodh

Magnusson

Malmfors

1977

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

This paper presents a review of the teratological and peri-and postnatal studies performed in rats and rabbits on FerastralB, an iron-poly (sorbitol-gluconic acid) complex.The test compound was given intramuscularly in doses varying from 1 to 100 mg Fe3+/kg. I n the teratological studies the compound was given daily during the whole or part of the period of organogenesis, and in the peri-and postnatal study in rats from day 16 of pregnancy through lactation to 21 days post partum. I n a separate study the effects of FerastralB on blood coagulation and fibrinolysis were studied in pregnant rats treated with 50 mg Fea+/kg. Jectoferm (iron-sorbitol) and ImferonB (iron-dextran)were used as reference compounds in some of the studies. Pregnant rats reacted in a totally different way compared to pregnant rabbits when treated with high doses of Ferastral. Pregnant rats, but not rabbits, developed focal necrosis in the liver, placenta and spleen. These changes were dose-dependent and not observed with lower doses ( 1, 4 and 16 mg Fe3+/kg). Similar pathological alterations were also seen after treatment with Jectofer, but not with Imferon. The pathological changes, being similar to those seen after elicitation of a generalized Shwartzman reaction (GSR),were not interpreted as an expression of such a reaction. The most common features of the GSR, bilateral cortical necrosis, capillary thrombi, and changes in the blood coagulation and fibrinolytic activity, were not observed in the pregnant rats. The maternal toxicity was accompanied by secondary effects on the foetuses manifested in reduced maturation of the foetal skeleton. Treatment with Ferastral in doses not inducing maternal toxicity did not adversely affect litter size, foetal loss, litter weight or embryonic or foetal development in either rats or rabbits.

show abstract

Parenteral Iron Therapy in Pregnancy

Cited by 20 publications

References 7 publications

The treatment of iron-deficiency anaemia by iron-dextran infusion, with special reference to the effect on blood-grouping, coagulation, sedimentation and haemolysis

The treatment of iron-deficiency anaemia by iron-dextran infusion, with special reference to the effect on blood-grouping, coagulation, sedimentation and haemolysis

Intravenous iron-dextran: studies on unsaturated iron-binding capacity

Teratological, Peri‐ and Postnatal Studies on Ferastral®, an Iron‐poly (sorbitol‐gluconic acid) complex

Contact Info

Product

Resources

About